Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd.
Your view on RGNT
Overview
What the company does, where it operates, and who runs it.
About Regentis Biomaterials Ltd.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Eli Hazum
- Headquarters
- IL
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Eli Hazum
- Headquarters
- IL
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients. Its lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries and articular knee cartilage.
The company focuses on developing orthopedic treatments using its Gelrin platform that is based on degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Regentis Biomaterials Ltd., and the rating behind it. RGNT last traded at $1.89; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Regentis Biomaterials Ltd.. Starting points for Regentis Biomaterials Ltd.: EPS -$24.16, beta -0.69 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Regentis Biomaterials Ltd.. Regentis Biomaterials Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Regentis Biomaterials Ltd.. Trailing twelve-month EPS for Regentis Biomaterials Ltd. stands at -$24.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Regentis Biomaterials Ltd.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Regentis Biomaterials Ltd. valued side by side against its closest peers. Regentis Biomaterials Ltd. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Regentis Biomaterials Ltd., and how their positions are changing. At a $13.3M market value, institutional positions materially move Regentis Biomaterials Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Regentis Biomaterials Ltd. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Regentis Biomaterials Ltd.. Regentis Biomaterials Ltd. is a $13.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Regentis Biomaterials Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Regentis Biomaterials Ltd.. Coverage tracks Regentis Biomaterials Ltd. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.